Skip to content
Lanreotide
Somatuline Depot (lanreotide) is a protein pharmaceutical. Lanreotide was first approved as Somatuline depot on 2007-08-30. It is used to treat acromegaly and neuroendocrine tumors in the USA. The pharmaceutical is active against somatostatin receptor type 2 and somatostatin receptor type 5. In addition, it is known to target somatostatin receptor type 3.
Download report
Favorite
Top 200 Pharmaceuticals by Retail Sales
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
neoplasmsD009369
musculoskeletal diseasesD009140
nervous system diseasesD009422
endocrine system diseasesD004700
Trade Name
FDA
EMA
Somatuline depot
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Lanreotide acetate
Tradename
Company
Number
Date
Products
LANREOTIDE ACETATECiplaN-215395 RX2021-12-17
3 products, RLD, RS
SOMATULINE DEPOTIpsenN-022074 RX2007-08-30
3 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
somatuline depotNew Drug Application2019-09-10
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
acromegaly—D000172—
neuroendocrine tumorsEFO_1001901D018358D3A.8
Agency Specific
FDA
EMA
Expiration
Code
LANREOTIDE ACETATE, SOMATULINE DEPOT, IPSEN PHARMA
2024-09-15ODE-156
Patent Expiration
No data
ATC Codes
H: Systemic hormonal preparations, excl. sex hormones and insulins
— H01: Pituitary and hypothalamic hormones and analogues
— H01C: Hypothalamic hormones
— H01CB: Somatostatin and analogues
— H01CB03: Lanreotide
HCPCS
Code
Description
J1930
Injection, lanreotide, 1 mg
Clinical
Clinical Trials
309 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
HygieneD006920—1404—45
Septic shockD012772A48.3—1211013
SepsisD018805A41.9——1157
HypotensionD007022EFO_0005251I9511—135
BurnsD002056T30.0——1113
Wounds and injuriesD014947T14.8———123
PsoriasisD011565EFO_0000676L40———213
Bacterial vaginosisD016585EFO_00039321——113
Atopic dermatitisD003876EFO_0000274L20———123
PneumoniaD011014EFO_0003106J18———112
Show 26 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients—1—7—412
HyperlactatemiaD065906——1—67
Macular degenerationD008268EFO_0001365H35.30—52——7
NeoplasmsD009369C802—2—15
Traumatic brain injuriesD000070642S06—22—25
ShockD012769R57.1—21—24
PancreatitisD010195EFO_0000278K85—11—23
Cardiopulmonary bypassD002315——1—23
Subarachnoid hemorrhageD013345EFO_0000713I60——1—23
Hemorrhagic shockD012771—11—13
Show 19 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Pancreatic neoplasmsD010190EFO_0003860C2521———3
Non-small-cell lung carcinomaD00228921———2
Prostatic neoplasmsD011471C61—2———2
Systemic sclerodermaD012595EFO_0000717M34—2———2
Heart arrestD006323EFO_0009492I46—1——12
Macular edemaD00826911———1
Retinal vein occlusionD012170EFO_1001157H34.8111———1
Diabetic retinopathyD003930EFO_0003770—1———1
StrokeD020521EFO_0000712I63.9—1———1
Intraoperative complicationsD007431—1———1
Show 15 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Pancreatic ductal carcinomaD0214411————1
Striae distensaeD057896HP_0001065L90.61————1
Type 2 diabetes mellitusD003924EFO_0001360E111————1
Dental cariesD003731EFO_0003819K021————1
Multiple myelomaD009101C90.01————1
ObesityD009765EFO_0001073E66.91————1
Prediabetic stateD011236EFO_1001121R73.031————1
Insulin resistanceD007333EFO_00026141————1
Non-alcoholic fatty liver diseaseD065626EFO_0003095K75.811————1
HyperinsulinismD006946HP_0000842E16.11————1
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Cesarean sectionD002585————55
Acute kidney injuryD058186HP_0001919N17————33
InflammationD007249————33
Critical illnessD016638————22
SeizuresD012640G40.4————22
MortalityD009026EFO_0004352————22
Postoperative complicationsD011183————22
Craniofacial abnormalitiesD019465————22
ArthrogryposisD001176EFO_0003857Q74.3————22
Infectious arthritisD001170EFO_1001351M00————22
Show 63 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameLANREOTIDE
INNlanreotide
Description
LANREOTIDE
Classification
Peptide
Drug classpeptides: inhibition of growth hormone release
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
CC(C)[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@@H](NC(=O)[C@H](N)Cc2ccc3ccccc3c2)CSSC[C@@H](C(=O)N[C@H](C(N)=O)[C@@H](C)O)NC1=O
Identifiers
PDB—
CAS-ID108736-35-2
RxCUI68092
ChEMBL IDCHEMBL1201185
ChEBI ID—
PubChem CID6918011
DrugBankDB06791
UNII ID0G3DE8943Y (ChemIDplus, GSRS)
Target
Agency Approved
SSTR2
SSTR2
SSTR5
SSTR5
Organism
Homo sapiens
Gene name
SSTR2
Gene synonyms
NCBI Gene ID
6752
Protein name
somatostatin receptor type 2
Protein synonyms
SRIF-1, SS2R
Uniprot ID
Q9BWH1
Mouse ortholog
Sstr2 (20606)
somatostatin receptor type 2 (Q91Y73)
Alternate
SSTR3
SSTR3
Organism
Homo sapiens
Gene name
SSTR3
Gene synonyms
NCBI Gene ID
6753
Protein name
somatostatin receptor type 3
Protein synonyms
SSR-28
Uniprot ID
Q53ZR7
Mouse ortholog
Sstr3 (20607)
somatostatin receptor type 3 (Q3UVV5)
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 2,929 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
217 adverse events reported
View more details